FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080492299> ?p ?o ?g. }

• W2080492299 endingPage "637" @default.
• W2080492299 startingPage "631" @default.
• W2080492299 abstract "To study if placebo-induced improvement in men with symptomatic benign prostatic hyperplasia (BPH) is maintained over 2 years, and to study the efficacy and safety from intervention with finasteride 5 mg for 24 months.This was a multicenter, double-blind, placebo-controlled study involving 707 patients with moderate symptoms of BPH enrolled at 59 centers in five Scandinavian countries. Following enrollment and a 4-week single-blind placebo run-in period, patients were randomized to receive finasteride 5 mg once daily or placebo for 24 months. Urinary symptoms, urinary flow rate, prostate volume, postvoiding residual urinary volume, and serum concentrations of prostate-specific antigen together with laboratory safety parameters were measured at entry and at months 12 and 24. Interim physical and laboratory examinations were performed when indicated clinically.In finasteride-treated patients the total symptom score improved throughout the study, with a significant difference between the two groups at 24 months (P < or = 0.01), whereas in placebo-treated patients, there was an initial improvement in the symptom score but no change from baseline at 24 months. The maximum urinary flow rate decreased in the placebo group, but improved in the finasteride group, resulting in a between-group difference of 1.8 mL/s at 24 months (P < or = 0.01). The mean change in prostate volume was +12% in the placebo group versus -19% in the finasteride-treated group (P < 0.01). Finasteride was generally well tolerated throughout the 2-year study period.The efficacy of therapy with finasteride 5 mg in improving both symptoms and maximum urinary flow rate and reducing prostate volume has been shown to be maintained during 24 months while patients receiving placebo experienced a return to baseline or deterioration of these parameters during the study. These results demonstrate that finasteride can reverse the natural progression of BPH." @default.
• W2080492299 created "2016-06-24" @default.
• W2080492299 creator A5002250651 @default.
• W2080492299 creator A5005490904 @default.
• W2080492299 creator A5014506703 @default.
• W2080492299 creator A5020239491 @default.
• W2080492299 creator A5045498384 @default.
• W2080492299 creator A5047479194 @default.
• W2080492299 creator A5048877153 @default.
• W2080492299 creator A5054400733 @default.
• W2080492299 date "1995-11-01" @default.
• W2080492299 modified "2023-10-14" @default.
• W2080492299 title "Can finasteride reverse the progress of benign prostatic hyperplasia? a two-year placebo-controlled study" @default.
• W2080492299 cites W107210901 @default.
• W2080492299 cites W129287562 @default.
• W2080492299 cites W1545591640 @default.
• W2080492299 cites W2039211272 @default.
• W2080492299 cites W2082063904 @default.
• W2080492299 cites W2118606175 @default.
• W2080492299 cites W2154718172 @default.
• W2080492299 cites W2247345803 @default.
• W2080492299 cites W2335425470 @default.
• W2080492299 cites W2337196267 @default.
• W2080492299 cites W2399251854 @default.
• W2080492299 cites W2417950888 @default.
• W2080492299 cites W4251469393 @default.
• W2080492299 cites W50881152 @default.
• W2080492299 cites W67598519 @default.
• W2080492299 doi "https://doi.org/10.1016/s0090-4295(99)80291-x" @default.
• W2080492299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7495111" @default.
• W2080492299 hasPublicationYear "1995" @default.
• W2080492299 type Work @default.
• W2080492299 sameAs 2080492299 @default.
• W2080492299 citedByCount "145" @default.
• W2080492299 countsByYear W20804922992012 @default.
• W2080492299 countsByYear W20804922992013 @default.
• W2080492299 countsByYear W20804922992014 @default.
• W2080492299 countsByYear W20804922992015 @default.
• W2080492299 countsByYear W20804922992016 @default.
• W2080492299 countsByYear W20804922992017 @default.
• W2080492299 countsByYear W20804922992019 @default.
• W2080492299 countsByYear W20804922992020 @default.
• W2080492299 countsByYear W20804922992021 @default.
• W2080492299 countsByYear W20804922992022 @default.
• W2080492299 countsByYear W20804922992023 @default.
• W2080492299 crossrefType "journal-article" @default.
• W2080492299 hasAuthorship W2080492299A5002250651 @default.
• W2080492299 hasAuthorship W2080492299A5005490904 @default.
• W2080492299 hasAuthorship W2080492299A5014506703 @default.
• W2080492299 hasAuthorship W2080492299A5020239491 @default.
• W2080492299 hasAuthorship W2080492299A5045498384 @default.
• W2080492299 hasAuthorship W2080492299A5047479194 @default.
• W2080492299 hasAuthorship W2080492299A5048877153 @default.
• W2080492299 hasAuthorship W2080492299A5054400733 @default.
• W2080492299 hasConcept C121608353 @default.
• W2080492299 hasConcept C126322002 @default.
• W2080492299 hasConcept C126894567 @default.
• W2080492299 hasConcept C142724271 @default.
• W2080492299 hasConcept C168563851 @default.
• W2080492299 hasConcept C204787440 @default.
• W2080492299 hasConcept C27081682 @default.
• W2080492299 hasConcept C2775874879 @default.
• W2080492299 hasConcept C2776235491 @default.
• W2080492299 hasConcept C2776547966 @default.
• W2080492299 hasConcept C2777562237 @default.
• W2080492299 hasConcept C2779478474 @default.
• W2080492299 hasConcept C2781406297 @default.
• W2080492299 hasConcept C61943457 @default.
• W2080492299 hasConcept C71924100 @default.
• W2080492299 hasConcept C77411442 @default.
• W2080492299 hasConceptScore W2080492299C121608353 @default.
• W2080492299 hasConceptScore W2080492299C126322002 @default.
• W2080492299 hasConceptScore W2080492299C126894567 @default.
• W2080492299 hasConceptScore W2080492299C142724271 @default.
• W2080492299 hasConceptScore W2080492299C168563851 @default.
• W2080492299 hasConceptScore W2080492299C204787440 @default.
• W2080492299 hasConceptScore W2080492299C27081682 @default.
• W2080492299 hasConceptScore W2080492299C2775874879 @default.
• W2080492299 hasConceptScore W2080492299C2776235491 @default.
• W2080492299 hasConceptScore W2080492299C2776547966 @default.
• W2080492299 hasConceptScore W2080492299C2777562237 @default.
• W2080492299 hasConceptScore W2080492299C2779478474 @default.
• W2080492299 hasConceptScore W2080492299C2781406297 @default.
• W2080492299 hasConceptScore W2080492299C61943457 @default.
• W2080492299 hasConceptScore W2080492299C71924100 @default.
• W2080492299 hasConceptScore W2080492299C77411442 @default.
• W2080492299 hasIssue "5" @default.
• W2080492299 hasLocation W20804922991 @default.
• W2080492299 hasLocation W20804922992 @default.
• W2080492299 hasOpenAccess W2080492299 @default.
• W2080492299 hasPrimaryLocation W20804922991 @default.
• W2080492299 hasRelatedWork W1485506175 @default.
• W2080492299 hasRelatedWork W1969544706 @default.
• W2080492299 hasRelatedWork W1971667801 @default.
• W2080492299 hasRelatedWork W2043149843 @default.
• W2080492299 hasRelatedWork W2066550653 @default.
• W2080492299 hasRelatedWork W2080492299 @default.
• W2080492299 hasRelatedWork W2082637341 @default.

• next